CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision
pharmaphorum
JULY 25, 2022
The CHMP has backed approval of Tecvayli for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies – including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody – setting up a full approval in the coming weeks. .
52 
Let's personalize your content